Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.
This study investigated the antiemetic activity of two different acute antiemesis regimens in patients receiving cisplatin-based chemotherapy. Seventy-four patients were treated with high-dose metoclopramide, dexamethasone and lorazepam (MDL) and 71 patients received high-dose alizapride, dexamethasone and lorazepam (ADL). Complete protection from vomiting was 50% in MDL-treated patients as compared with 30% in the ADL arm (p = 0.04). Incidence of delayed emesis was assessed in the first 82 patients accrued for the 120 h postcisplatin, being 69 and 60% in MDL and ADL, respectively.
Moreno
I
I
Hospital de Badalona Germans Trias i Pujol, Medical Oncology Unit, Barcelona, Spain.
Rosell
R
R
Abad-Esteve
A
A
Barnadas
A
A
Carles
J
J
Ribelles
N
N
D000932:Antiemetics / Q000008:administration & dosage*; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage*; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage*; D008787:Metoclopramide / Q000008:administration & dosage*; D009325:Nausea / Q000139:chemically induced; D011446:Prospective Studies; D011759:Pyrrolidines / Q000008:administration & dosage*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D011759:Pyrrolidines; D003907:Dexamethasone; D008787:Metoclopramide; D008140:Lorazepam; C033968:alizapride; D002945:Cisplatin